Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

sIL2R ratio as early marker for response in hairy cell leukemia and the prognostic relevance of IL28B genotype to interferon-α therapy.

Annals of hematology - 1 May 2017

Jud Stéphanie, Goede Jeroen S, Senn Oliver, Spanaus Katharina, Manz Markus G, Benz Rudolf

Abstract excerpt

Interferon-α (IFNα) was the first effective drug therapy for hairy cell leukemia (HCL). Nowadays, it is used as an alternative treatment in selected patients. Due to unlimited treatment time, monitoring and early prediction of response are important. Moreover, IFNα is used in the therapy of chronic hepatitis C, where a single nucleotide polymorphism of interleukin-28B gene (IL28B) correlates with therapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferons

Share to Interleukins

Share to Leukemia, Hairy Cell

Share to Neoplasms, Second Primary

Share to Receptors, Interleukin-2

Share to Recurrence

Source

Identifiers

PMID: 28214980
DOI: 10.1007/s00277-017-2943-8

Genes

CDA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

sIL2R ratio as early marker for response in hairy cell leukemia and the prognostic relevance of IL28B genotype to interferon-α therapy.PMID 28214980Read ↗

The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C.Semantic proximity Read ↗

Impact of interleukin 28B rs12979860 C/T polymorphism on severity of disease and response to treatment in hepatitis delta.Semantic proximity Read ↗

Interleukin28B and inosine triphosphatase help to personalize hepatitis C treatment.Semantic proximity Read ↗

Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms.Semantic proximity Read ↗

The Role of Interferon-&#x03BB; Locus Polymorphisms in Hepatitis C and Other Infectious DiseasesSemantic proximity Read ↗

Life Expectancy of Hairy Cell Leukemia Patients Approaches General Population: Insights from a SEER Study of 5669 CasesSemantic proximity Read ↗

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virusSemantic proximity Read ↗

Distinct and overlapping genomic profiles and antiviral effects of Interferon‐λ and ‐α on HCV‐infected and noninfected hepatoma cellsSemantic proximity Read ↗

Interferon-lambda and therapy for chronic hepatitis C virus infection.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.Semantic proximity Read ↗

[IL28B genetic variation and hepatic ISGs expression predict treatment efficacy of IFN-based anti-viral therapy for chronic hepatitis C].Semantic proximity Read ↗

Gene-disease association with human IFNL locus polymorphisms extends beyond hepatitis C virus infections.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.